Bristol-Myers Squibb Company Company Profile (NYSE:BMY)

About Bristol-Myers Squibb Company (NYSE:BMY)

Bristol-Myers Squibb Company logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:BMY
  • CUSIP: 11012210
  • Web:
  • Market Cap: $103.90571 billion
  • Outstanding Shares: 1,639,926,000
Average Prices:
  • 50 Day Moving Avg: $58.94
  • 200 Day Moving Avg: $56.02
  • 52 Week Range: $46.01 - $63.55
  • Trailing P/E Ratio: 23.14
  • Foreward P/E Ratio: 20.24
  • P/E Growth: 2.34
Sales & Book Value:
  • Annual Revenue: $20.24 billion
  • Price / Sales: 5.13
  • Book Value: $8.96 per share
  • Price / Book: 7.07
  • Annual Dividend: $1.56
  • Dividend Yield: 2.5%
  • EBIDTA: $6.01 billion
  • Net Margins: 22.66%
  • Return on Equity: 32.33%
  • Return on Assets: 14.86%
  • Debt-to-Equity Ratio: 0.47%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.45%
  • Average Volume: 6.59 million shs.
  • Beta: 1.18
  • Short Ratio: 2.45

Frequently Asked Questions for Bristol-Myers Squibb Company (NYSE:BMY)

What is Bristol-Myers Squibb Company's stock symbol?

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company announced a quarterly dividend on Wednesday, September 13th. Investors of record on Friday, October 6th will be paid a dividend of $0.39 per share on Wednesday, November 1st. This represents a $1.56 annualized dividend and a dividend yield of 2.46%. The ex-dividend date is Thursday, October 5th. View Bristol-Myers Squibb Company's Dividend History.

How were Bristol-Myers Squibb Company's earnings last quarter?

Bristol-Myers Squibb Company (NYSE:BMY) posted its quarterly earnings results on Thursday, July, 27th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. The business earned $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb Company had a return on equity of 32.33% and a net margin of 22.66%. The business's quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company posted $0.69 earnings per share. View Bristol-Myers Squibb Company's Earnings History.

When will Bristol-Myers Squibb Company make its next earnings announcement?

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Bristol-Myers Squibb Company.

What guidance has Bristol-Myers Squibb Company issued on next quarter's earnings?

Bristol-Myers Squibb Company issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.94.

Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?

18 brokerages have issued 1 year price objectives for Bristol-Myers Squibb Company's shares. Their predictions range from $49.00 to $75.00. On average, they anticipate Bristol-Myers Squibb Company's stock price to reach $61.54 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb Company.

What are analysts saying about Bristol-Myers Squibb Company stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

  • 1. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
  • 2. Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • 3. According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)
  • 4. BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)

Who are some of Bristol-Myers Squibb Company's key competitors?

Who are Bristol-Myers Squibb Company's key executives?

Bristol-Myers Squibb Company's management team includes the folowing people:

  • Giovanni Caforio M.D., Chairman of the Board, Chief Executive Officer
  • Charles A. Bancroft, Chief Financial Officer and Executive Vice President - Global Business Operations
  • Louis S. Schmukler, President - Global Manufacturing and Supply
  • Ann Powell Judge, Chief Human Resource Officer, Senior Vice President
  • Thomas J. Lynch Jr., M.D., Ph.D., Executive Vice President, Chief Scientific Officer
  • Sandra Leung, Executive Vice President, General Counsel
  • Murdo Gordon, Executive Vice President, Chief Commercial Officer
  • Paul von Autenried, Senior Vice President, Chief Information Officer
  • Anne Nielsen, Senior Vice President, Chief Compliance and Ethics Officer
  • Joseph C. Caldarella, Senior Vice President, Corporate Controller

Who owns Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.24%), BlackRock Inc. (6.06%), State Street Corp (4.13%), FMR LLC (2.23%), Capital World Investors (1.93%) and Dodge & Cox (1.80%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler, Sandra Leung and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb Company.

Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Capital World Investors, Bank of Montreal Can, Thrivent Financial For Lutherans, Bessemer Group Inc., TIAA CREF Investment Management LLC, William Blair Investment Management LLC and Manning & Napier Advisors LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler and Sandra Leung. View Insider Buying and Selling for Bristol-Myers Squibb Company.

Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc., Janus Henderson Group PLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Jennison Associates LLC, Harbour Capital Advisors LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for Bristol-Myers Squibb Company.

How do I buy Bristol-Myers Squibb Company stock?

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb Company's stock price today?

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $63.36.

MarketBeat Community Rating for Bristol-Myers Squibb Company (NYSE BMY)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  638 (Vote Outperform)
Underperform Votes:  607 (Vote Underperform)
Total Votes:  1,245
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $61.54 (2.87% downside)

Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Cowen and CompanyReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/11/2017Jefferies Group LLCBoost Price TargetBuy$66.00 -> $72.00LowView Rating Details
9/8/2017Credit Suisse GroupReiterated RatingNeutral -> HoldLowView Rating Details
9/7/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$62.00 -> $65.00LowView Rating Details
9/4/2017BMO Capital MarketsReiterated RatingSell$49.00LowView Rating Details
7/28/2017Leerink SwannLower Price TargetOutperform$66.00 -> $61.00LowView Rating Details
7/27/2017Piper Jaffray CompaniesSet Price TargetHold$60.00MediumView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetHold$54.00 -> $55.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/22/2017ArgusReiterated RatingBuy$75.00N/AView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/24/2017Barclays PLCLower Price TargetEqual Weight$65.00 -> $58.00N/AView Rating Details
1/21/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
11/8/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
10/10/2016SunTrust Banks, Inc.Reiterated RatingHold$68.00 -> $62.00N/AView Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldN/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00N/AView Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Earnings History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017$0.75N/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.09 billion$5.14 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.75 billion$4.93 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
2017 EPS Consensus Estimate: $2.82
2018 EPS Consensus Estimate: $3.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.70$0.72$0.71
Q2 20173$0.70$0.76$0.73
Q3 20173$0.70$0.75$0.72
Q4 20173$0.62$0.68$0.65
Q1 20181$0.75$0.75$0.75
Q2 20181$0.75$0.75$0.75
Q3 20181$0.78$0.78$0.78
Q4 20181$0.76$0.76$0.76
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
Next Dividend:11/1/2017
Annual Dividend:$1.56
Dividend Yield:2.46%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:56.73% (Trailing 12 Months of Earnings)
52.35% (Based on This Year's Estimates)
49.84% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Dividend History by Quarter for Bristol-Myers Squibb Company (NYSE BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.88%
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Trades by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.00View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.00View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.00View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.84View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.00View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Bristol-Myers Squibb Company (NYSE:BMY)
Latest Headlines for Bristol-Myers Squibb Company (NYSE:BMY)
DateHeadline logoBristol-Myers Squibb Company (BMY) Earns Hold Rating from Cowen and Company - September 24 at 2:44 PM logoBristol-Myers Squibb (BMY) Granted Approval by Japanese Ministry of Health for Opdivo (nivolumab) Based on 3 Study ... - - September 23 at 1:38 AM logoAbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate Therapeutic Regimen in Advanced Solid Tumors - - September 23 at 1:37 AM logoBRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients - September 22 at 8:37 PM logoBristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib - September 22 at 8:37 PM logoBRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors - September 22 at 10:58 AM logoJapan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy - September 22 at 10:58 AM logoAbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors - September 22 at 10:57 AM logoBristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference - Business Wire (press release) - September 21 at 4:25 PM logoNew Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors - September 21 at 11:30 AM logoBristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference - September 21 at 11:30 AM logo2 Important Dates for Big Pharma - September 20 at 10:33 PM logoBristol-Myers' Opdivo available to a number of lung cancer patients in England through special fund - September 20 at 5:24 PM logoBuy Bristol-Myers Squibb Co (BMY) Stock With No Fear - - September 19 at 4:40 PM logoOpdivo In Focus After BMY's Checkmate-214 Study Being Stopped Early - September 18 at 5:00 PM logoThe Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017 - September 18 at 5:00 PM logoBuy Bristol-Myers Squibb Co (BMY) Stock With No Fear - September 18 at 10:31 AM logoJefferies Group Comments on Bristol-Myers Squibb Company's FY2017 Earnings (BMY) - September 18 at 3:42 AM logoSunTrust Banks Brokers Reduce Earnings Estimates for Bristol-Myers Squibb Company (BMY) - September 18 at 3:22 AM logoBristol-Myers Squibb Stock Still a Beast? - September 17 at 4:18 PM logoBristol-Myers Squibb Target of Unusually High Options Trading (BMY) - September 17 at 2:20 AM logoHalozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? - September 16 at 4:18 PM logoBristol-Myers Squibb Company (BMY) Expected to Post Quarterly Sales of $5.15 Billion - September 16 at 7:24 AM
News IconBRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology - September 15 at 5:02 PM logoBristol-Myers (BMY) Collaborates With Halozyme for ENHANZE - September 15 at 5:02 PM logoTime to Adjust as Bristol-Myers Squibb Continues Its Climb - September 15 at 5:01 PM logoHalozyme Jumps on Immuno-Oncology Deal with Bristol-Myers - September 15 at 3:24 AM logoHalozyme out-licenses ENHANZE to Roche and Bristol Myers for up to $455M; raises guidance; shares up 12 ... - Seeking Alpha - September 14 at 10:20 PM logo$0.75 Earnings Per Share Expected for Bristol-Myers Squibb Company (BMY) This Quarter - September 14 at 6:30 PM logoExelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale - Motley Fool - September 14 at 5:18 PM logoDaily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA - Nasdaq - September 14 at 5:18 PM logoBristol-Myers Squibb (BMY) Names Karen Vousden to Board of Directors - - September 14 at 5:18 PM logoHalozyme to license drug delivery tech to Bristol-Myers a... - September 14 at 5:17 PM logoThis Small Cap Biotech Soars On Deals With Bristol-Myers, Roche - September 14 at 5:17 PM logoBristol-Myers Stock May Be Fully Valued - September 14 at 3:53 AM logoBristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors - Business Wire (press release) - September 13 at 5:47 PM logo[$$] Bristol-Myers Stock May Be Fully Valued - September 13 at 5:47 PM logoBristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors - September 13 at 5:47 PM logoBristol-Myers Squibb Announces Dividend - September 13 at 5:47 PM logoBristol-Myers Squibb Company (BMY) Declares Quarterly Dividend of $0.39 - September 13 at 4:50 PM logoBrokers Issue Forecasts for Bristol-Myers Squibb Company's Q1 2018 Earnings (BMY) - September 13 at 10:14 AM logoBristol-Myers Reports Positive Results from Melanoma Study - Nasdaq - September 13 at 3:08 AM logoHilliard Lyons Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral - - September 12 at 5:02 PM logoCompany News For Sep 12, 2017 - September 12 at 5:02 PM logoBristol-Myers Squibb Company (BMY) Stock Rating Lowered by Hilliard Lyons - September 12 at 9:32 AM logoBristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 Trial - September 12 at 3:20 AM logoBristol-Myers Squibb (BMY) Presents at Morgan Stanley Healthcare Conference (Transcript) - September 11 at 10:18 PM logoCancer immunotherapy proves itself in earlier-stage disease - September 11 at 10:18 PM logoBristol-Myers Squibb Company (BMY) Given "Buy" Rating at Jefferies Group LLC - September 11 at 5:46 PM logoOpdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study - September 10 at 9:19 PM



Bristol-Myers Squibb Company (BMY) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff